HC Wainwright Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price

Liquidia (NASDAQ:LQDA) had its target price lifted by stock analysts at HC Wainwright from $50.00 to $55.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 59.33% from the company’s current price. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, FY2025 earnings at ($0.64) EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS, FY2029 earnings at $7.57 EPS and FY2030 earnings at $9.85 EPS.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Jefferies Financial Group upped their target price on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Finally, BTIG Research restated a “buy” rating and issued a $49.00 price target on shares of Liquidia in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $40.56.

Liquidia Price Performance

LQDA opened at $34.52 on Friday. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The stock has a market capitalization of $3.00 billion, a P/E ratio of -23.97, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52. The company’s 50 day simple moving average is $37.07 and its 200-day simple moving average is $30.84. Liquidia has a one year low of $11.26 and a one year high of $46.67.

Liquidia (NASDAQ:LQDA) last released its earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $92.02 million during the quarter. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm’s revenue was up 3072.4% compared to the same quarter last year. Sell-side analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 66,610 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $2,493,212.30. Following the completion of the sale, the chief executive officer directly owned 1,037,528 shares in the company, valued at $38,834,673.04. This represents a 6.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Kaseta sold 36,932 shares of Liquidia stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares in the company, valued at $13,134,898.17. This trade represents a 9.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 212,534 shares of company stock valued at $7,964,719. Insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several large investors have recently made changes to their positions in LQDA. Seven Fleet Capital Management LP acquired a new position in Liquidia in the 4th quarter worth $3,148,000. Invesco Ltd. grew its stake in shares of Liquidia by 428.3% during the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock worth $14,507,000 after acquiring an additional 341,009 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Liquidia in the fourth quarter valued at approximately $1,214,000. nVerses Capital LLC acquired a new position in Liquidia during the fourth quarter worth $335,000. Finally, Occudo Quantitative Strategies LP bought a new position in Liquidia in the fourth quarter valued at $3,107,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non?GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).